Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
170.50
-8.00 (-4.48%)
Oct 7, 2025, 11:46 AM CST
-4.48%
Market Cap276.86B
Revenue (ttm)44.83M
Net Income (ttm)-618.09M
Shares Out1.55B
EPS (ttm)-0.41
PE Ration/a
Forward PE77.95
Dividendn/a
Ex-Dividend Daten/a
Volume11,027,954
Average Volume28,371,787
Open178.00
Previous Close178.50
Day's Range170.00 - 181.00
52-Week Range43.60 - 277.00
Beta0.91
RSI41.44
Earnings DateNov 7, 2025

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.

Financial Statements

News

There is no news available yet.